Arcutis Biotherapeutics, Inc.
ARQT
Rank in Stocks
#4371
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Share Price
$28.54
Last synced: 2026-10-16
Market Cap
$3.59B
Change (1 day)
-1.94%
Change (1 year)
36.66%
Country
US
Trade Arcutis Biotherapeutics, Inc. (ARQT)
Category
Healthcare
EPS for Arcutis Biotherapeutics, Inc. (ARQT)
EPS as of June 2026 TTM: $0.22
According to Arcutis Biotherapeutics, Inc. latest financial reports and stock price the company's current EPS (TTM) is $0.22. At the end of 2023 the company had a EPS of $-3.78 a decrease compared to its 2022 EPS that were of $-5.66.
EPS history for Arcutis Biotherapeutics, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.22 | -118.97% |
| 2024 | $-1.16 | -69.31% |
| 2023 | $-3.78 | -33.22% |
| 2022 | $-5.66 | 35.73% |
| 2021 | $-4.17 | 9.74% |
| 2020 | $-3.80 | 245.45% |
| 2019 | $-1.10 | 107.55% |
| 2018 | $-0.53 | -88.75% |
| 2017 | $-4.71 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | 7,772.73% |
US
|
|
| $-7.98 | -3,727.27% |
US
|
|
| $-5.29 | -2,504.55% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 12,509.09% |
NL
|
